R289
Small molecule
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05308264 NCT05308264 · Myelodysplastic Syndromes Registry: NCT05308264 | 1/2 | Safety and Tolerability (2 Year) 2027-12 | In progress: results expected 1 Dec 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Myelodysplastic Syndromes: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| R289: this drug | Phase 1/2 | Small molecule | IRAK1/IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Azacitidine | Approved | Small molecule | DNMT1 (DNA methyltransferase 1) | not yet graded | No reviewed efficacy summary in this indication | |
| Decitabine / Cedazuridine (Inqovi) | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | Partial signal | Featured results are non-efficacy only in this race | |
| Imetelstat (Rytelo) | Approved | RNA / oligonucleotide | Telomerase | Reliable signal | No reviewed efficacy summary in this indication | |
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | not yet graded | No reviewed efficacy summary in this indication | |
| Elritercept | Phase 3 | Undisclosed | Activin A/B | not yet graded | No reviewed efficacy summary in this indication | |
| Roxadustat (Evrenzo) | Phase 3 | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | not yet graded | No reviewed efficacy summary in this indication | |
| AND017 | Phase 2 | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | not yet graded | No reviewed efficacy summary in this indication | |
| Momelotinib | Phase 2 | Small molecule | JAK1 / JAK2 / ACVR1 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08046040 | —(overall) | Undisclosed | CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70 | not yet graded | No reviewed efficacy summary in this indication | |
| REGN17235 | —(overall) | Multispecific antibody | SLC3A2 x CD3 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow R289 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.